

09/743682  
522 Rec'd PCT/PTO 10 JAN 2001

Practitioner's Docket No. 586.02-US1

PATENT

Preliminary Classification:

Proposed Class:

Subclass:

**TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US)--  
ENTRY INTO THE U.S. NATIONAL STAGE UNDER CHAPTER I**

PCT/IB00/00673	19 May 2000 (19.05.00)	20 May 1999 (20.05.99)
International Application Number	International Filing Date	International Earliest Priority Date

TITLE OF INVENTION: DIFFERENTIALLY EXPRESSED GENES IN PROSTATE CANCER

APPLICANT(S) FOR DO/US: SAATCIOGLU, Fahri

**Box PCT**  
**Assistant Commissioner for Patents**  
**Washington D.C. 20231**  
**ATTENTION: DO/US**

**CERTIFICATION UNDER 37 C.F.R. section 1.10\***

(Express Mail label number is **mandatory**.)

(Express Mail certification is **optional**.)

I hereby certify that this paper, along with any document referred to, is being deposited with the United States Postal Service on this date **January 10, 2001**, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number **EL733694043US**, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Kristin J. Azcona

**WARNING:** Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. section 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).  
"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Transmittal Letter to the United States Designated Office (DO/US - Entry into National Stage under 35 U.S.C. section 371--  
page 1 of 3)

1. Applicant herewith submits to the United States Designated Office (DO/US) the following items under 35 U.S.C. section 371:

This express request to immediately begin national examination procedures (35 U.S.C. section 371(f)).  
The U.S. National Fee (U.S.C. section 371(c)(1)), as indicated below:

2. Fees

CLAIMS FEE*	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
BASIC FEE	TOTAL CLAIMS	36 -20 =	16	x \$18.00 =	\$288.00
	INDEPENDENT CLAIMS	13 -3 =	10	x \$80.00 =	\$800.00
	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$270				\$0.00
	The international search fee, as set forth in Section 1.445(a)(2) to be paid to the US PTO acting as an international Searching Authority:  where a search report on the international application has been prepared by the European Patent Office or the Japanese Patent Office (37 CFR 1.492(a)(5)) .....\$860.00				\$860.00
	Total of above Calculations				= \$1,948.00
SMALL ENTITY	Reduction by 1/2 for filing by small entity, if applicable. Affidavit must be filed (note 37 CFR 1.9, 1.27, 1.28).				- \$974.00
	Subtotal				\$974.00
	Total National Fee				\$974.00
	Fee for recording the enclosed assignment document \$40.00 (37 CFR 1.21(h)). (See Item below). See attached "ASSIGNMENT COVER SHEET".				\$0.00
TOTAL	Total Fees enclosed				\$974.00

A check in the amount of \$974.00 to cover the above fees is enclosed.

3. A copy of the International application as filed (35 U.S.C. section 371(c)(2)) is transmitted herewith.

4. A translation of the International application into the English language (35 U.S.C. section 371(c)(2)) is not required as the application was filed in English.

5. Amendments to the claims of the International application under PCT Article 19 (35 U.S.C. section 371(c)(3)) are transmitted herewith.

6. An oath or declaration, including power of attorney, of the inventor (35 U.S.C. section 371(c)(4)) complying with 35 U.S.C. section 115 is submitted herewith, and such oath or declaration is attached to application.

II. Other document(s) or information included:

7. An international Search Report or Declaration under PCT Article 17(2)(a) will be transmitted promptly upon request.

8. An Information Disclosure Statement under 37 C.F.R. sections 1.97 and 1.98 will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. § 371(c).

9. Additional documents:

Copy of request (PCT/RO/101)  
International Publication No. WO00/71700  
Specification, claims and drawing  
Preliminary amendment (37 C.F.R. section 1.121)

10. The above checked items are being transmitted after publication and the article 20 communication, but before 20 months from the priority date.

**AUTHORIZATION TO CHARGE ADDITIONAL FEES**

The Commissioner is hereby authorized to charge the following additional fees that may be required by this paper and during the entire pendency of this application to Account No. 500341.

37 C.F.R. section 1.492(a)(1), (2), (3), and (4) (filing fees)

37 C.F.R. section 1.492(b), (c), and (d) (presentation of extra claims)

37 C.F.R. section 1.17 (application processing fees)

37 C.F.R. section 1.17(a)(1)-(5) (extension fees pursuant to section 1.136(a))

Date: January 10, 2001



Robert D. Fish  
Fish & Associates, LLP  
1440 N. Harbor Blvd.  
Suite 706  
Fullerton, CA 92835  
USA

Practitioner Docket No. 586.02-US1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231**

Inventor: **Fahri Saatcioglu**

Examiner: **Not Yet Assigned**

Serial No: **U.S. National Phase  
Application of PCT/IB00/00673**

Art Unit: **Not Yet Assigned**

Filed: **May 19, 2000**

For: **Differentially Expressed  
Genes in Prostate Cancer**

**PRELIMINARY AMENDMENT**

The Honorable Commissioner  
of Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

Please enter the following preliminary amendment:

**IN THE CLAIMS**

5. (Amended) The polynucleotide of [any one of] claim 1[, 3, or 4] wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.
6. (Amended) The polynucleotide of [any one of] claim 1[, 3, or 4] wherein the expression of the polynucleotide is dependent on at least one of an androgen, a progesterone, an estrogen, and a glucocorticoid.
33. (Added ) The polynucleotide of claim 3 wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.
34. (Added ) The polynucleotide of claim 4 wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.

35. (Added) The polynucleotide of claim 3 wherein the expression of the polynucleotide is dependent on at least one of an androgen, a progesterone, an estrogen, and a glucocorticoid.

36. (Added) The polynucleotide of claim 4 wherein the expression of the polynucleotide is dependent on at least one of an androgen, a progesterone, an estrogen, and a glucocorticoid.

### **REMARKS**

The foregoing amendments simply eliminate the multiple dependency of claims 5 and 6. No new matter has been added.


### **REQUEST FOR ALLOWANCE**

Claims 1-36 are pending in this application. The applicants request allowance of all pending claims.

Respectfully submitted,

Fish & Associates, LLP

Dated: January 19, 2001

By:   
Robert D. Fish  
Reg. No. 33,880

Attorneys for Applicant(s)  
1440 N. Harbor Blvd., Suite 706  
Fullerton, CA 92835  
Tel.: (714) 449-2337  
Fax: (714) 449-2339

## DIFFERENTIALLY EXPRESSED GENES IN PROSTATE CANCER

This application claims the benefit of U.S. provisional application number 60/135,325 filed May 20, 1999, and U.S. provisional application number 60/135,333 filed May 20, 1999, both of which are incorporated herein by reference in their entirety.

### 5 Field of The Invention

The field of the invention is neoplastic diseases, and especially detection and therapy of prostate cancer.

### Background of The Invention

Prostate cancer has become the most commonly diagnosed malignancy in males in the western world, and is the second most common cause of cancer death among men in Europe and the United States (Boring, C.C., Squires, T.S., and Tong, T. (1993). *Cancer J. Clin.* 43, 7-26; Carter, H.B., Pianpadosi, S., and Isaacs, J.T. (1990). *J. Urol.* 143, 742-746). Worse yet, in recent years the annual incidence rate of newly diagnosed prostate cancer, as well as the number of prostate cancer deaths continuously rose.

Androgens not only play a key role in the development and maintenance of the normal prostate, but also in the initiation and progression of prostate cancer (Moore, R.A. (1944). *Surgery* 16, 152-167; Huggins, C., and Johnson, M.A. (1947). *J. Am. Med. Assoc.* 135, 1146-1152). For example, androgens typically induce cell proliferation and inhibit cell death in the healthy prostate gland. Withdrawal of androgens stops proliferation of cells and induces apoptosis with concomitant involution of the prostate gland. Involution upon androgen withdrawal is generally a characteristic of a normal prostate gland as well as of a prostate tumor in the early stages of the disease, when the tumor still remains androgen dependent. Consequently, androgen withdrawal treatment is commonly used to reverse tumor growth. However, in the case of many prostate tumors, the tumor recurs after a few months or years almost invariably in an androgen insensitive state. At this point, successful therapy of prostate cancer is difficult and prognosis for survival is usually relatively low.

Almost all of the biological effects of androgens are mediated by the androgen receptor, a hormone-activated transcription factor. Even though the androgen receptor was cloned over ten years ago, the mechanisms by which the androgen receptor regulates gene expression is not well-

understood. Furthermore, only a very few of its target genes have been identified, including the prostate specific antigen (PSA), the related glandular kallikrein 2 (hKLK2), and the androgen receptor itself. Another androgen regulated protein, a secreted serine protease with prostate restricted expression, termed "prostase" was recently described by Nelson et al. (Nelson, P.S., et al. (1999) *Proc. Natl. Acad. Sci.* 96, 3114-3119). However, the biological functions of the proteins coded by the PSA, hKLK2 and prostase genes are poorly understood at present.

Adding to the difficulties in understanding the role of androgens in prostate cancer is that *in vivo* and *in vitro* model systems frequently do not closely mimic the human disease.

Furthermore, close homologues of the PSA gene, the only marker for prostate cancer in human, are not known in other animal species. Moreover, *in vitro* studies are hampered due to the limited number of cell lines that have been derived from human prostate. For example, the only androgen sensitive and androgen responsive cell line that is widely used is LNCaP, characterized by cells originally derived from a lymph node metastasis of a human prostate carcinoma (Horoszewicz, J.S., Leong, S.S., Kawinski, E., Karr, J.P., Rosenthal, H., Chu, T.M., Mirand, E.A., and Murphy, G.P. (1983). *Cancer Res.* 43, 1809-1818).

In spite of numerous studies on the effects of androgens in the role of prostate cancer, relatively little is known about the molecular genetic effects of androgens in prostate cells. More detailed knowledge about androgen responsive genes and their role in signal transduction, as well as gross morphological and physiological transformations will potentially result in better diagnostic tools, and provide possible new targets for a drug-based therapy of prostate cancer. Therefore, there is still a need to provide improved methods to identify androgen responsive, differentially expressed genes in prostate cancer.

### Summary of the Invention

The present invention is directed to differentially expressed genes in neoplastic cells, and particularly relates to hormone dependent genes in prostate cancer. The polynucleotides with the SEQ ID NO:1 - SEQ ID NO:7 encode an intracellular protein, and while the corresponding polypeptides SEQ ID NO:11 - SEQ ID NO:14 have an intracellular location, the corresponding expression products SEQ ID NO:8 - SEQ ID NO:10 have predominantly perinuclear, nuclear and predominantly nuclear localization within a cell, respectively.

In one aspect of the inventive subject matter, SEQ ID NO:1 - SEQ ID NO:7 are expressed in prostate cancer cells in a hormone dependent manner.

In another aspect of the inventive subject matter, a method of detecting a neoplastic cell in a system includes a step in which a predetermined amount of an RNA comprising at least one of SEQ ID NO:15 - SEQ ID NO:21 is correlated with the presence of a neoplastic cell, and the predetermined amount, or more, is subsequently detected in the system. Contemplated detection methods preferably employ a labeled probe that is detectable via fluorescence detection, luminescence detection, scintigraphy, autoradiography, or formation of a dye. Alternative preferred detection methods include addition of at least one nucleotide to the probe (*e.g.*, PCR, LCR).

In a further aspect of the inventive subject matter, a method of detecting a neoplastic cell in a system includes a step in which a predetermined amount of a polypeptide comprising at least one of SEQ ID NO:8 - SEQ ID NO:14 is correlated with the presence of a neoplastic cell, and the predetermined amount, or more, is subsequently detected in the system. Contemplated detection methods preferably employ a labeled probe that is detectable via fluorescence detection, luminescence detection, scintigraphy, autoradiography, or formation of a dye, and preferred probes include antibodies, antibody fragments, and natural and synthetic ligands of the polypeptide.

In a still further aspect of the inventive subject matter, a method of identifying differentially expressed genes in a target tissue has one step in which a target tissue-specific cDNA library is prepared by suppression subtractive hybridization, and a plurality of genes from the library is immobilized on a solid phase. Nucleic acid preparations from treated and untreated target tissue are individually hybridized with array, respectively, and hybridization patterns are compared to identify differentially expressed genes.

Various objects, features, aspects and advantages of the present invention will become more apparent from the following detailed description of preferred embodiments of the invention, along with the accompanying drawing.



### **Brief Description of The Drawing**

Figures 1A and 1B depict schematic nucleic acid and amino acid based multiple sequence alignments of SEQ ID NO:1 - SEQ ID NO:7 and SEQ ID NO:8 - SEQ ID NO:13, respectively.

5 Figure 2 is a photograph of an exemplary reverse northern blot of several clones from a cDNA library of androgen treated prostate cancer cells.

Figure 3 is a photograph of an exemplary multiple tissue northern blot of one of the isolated polynucleotides.

Figure 4 is a photograph of an agarose gel after electrophoretic separation of splicing variants of SEQ ID NO:1.

Figure 5 is a series of photomicrographs illustrating the intracellular localization of GFP-fusion proteins of polypeptides of SEQ ID NO:8 - SEQ ID NO:10.

Figure 6 is an autoradiograph of a northern blot indicating hormone dependent expression of SEQ ID NO:1 - SEQ ID NO:7.

### **Detailed Description**

As used herein, the term "intracellular protein" refers to a protein that is expressed and retained within a cell irrespective of its subcellular localization. For example, DNA polymerase (nucleus), glyceraldehyde-3-phosphate dehydrogenase (cytoplasm), and cytochrome c oxidase (mitochondria) are all considered intracellular proteins. In contrast, the term "extracellular protein" refers to a protein that is exported from a cell. There are various mechanisms by which a protein can be exported from a cell, all of which are contemplated herein. For example, while many exported proteins have a signal sequence that allows specific export of the protein across a cell membrane, other proteins are exported through vesicles via the endoplasmic reticulum, etc.

As also used herein, a protein has a "predominantly perinuclear localization" when a majority of the protein (*i.e.*, more than 50% of the total amount as fluorimetrically detectable by GFP-fusion) is located in a volume around the nucleus that does not exceed a volume greater than three volumes of the nucleus. A protein has a "predominantly nuclear localization" when a majority of the protein is located within the nucleus. In contrast, the term "nuclear localization"

means that substantially all of the detectable protein is located within the nucleus. Localization of a protein can be determined fluorimetrically by GFP-fusion (GFP: green fluorescence protein).

Employing a novel combined SSH-reverse northern blot procedure (first disclosed in provisional application 60/135,325 filed May 20, 1999), we isolated seven cDNAs (SEQ ID NO:1 - SEQ ID NO:7) from human prostate cancer cells. All seven cDNA molecules code for an intracellular protein, which is expressed in an androgen and glucocorticoid dependent manner. Remarkably, the sequences SEQ ID NO:1 - SEQ ID NO:7 show a high degree of homology/identity with prostase, a previously reported serine protease (Nelson, P.S., et al. (1999) *Proc. Natl. Acad. Sci.* 96, 3114-3119). However, in comparison with the prostase, all of the sequences SEQ ID NO:1 - SEQ ID NO:7 lack a 49 amino acid N-terminal portion corresponding to the first exon of the prostase. It should be especially appreciated that the first exon of the prostase not only includes structurally important amino acids, but also includes a signal peptide sequence that renders the serine protease a secreted, extracellular enzyme. Consequently, the cDNA molecules with the sequence of SEQ ID NO:1 - SEQ ID NO:7 encode intracellular proteins that are functionally and structurally different from the prostase, and are therefore independent and novel genes.

With respect to the base composition of SEQ ID NO:1 - SEQ ID NO:7, nucleotide sequences other than SEQ ID NO:1 - SEQ ID NO:7 are also contemplated and particularly include variations of SEQ ID NO:1 - SEQ ID NO:7 that include point mutations, insertions, deletions and any reasonable combination thereof, so long as alternative sequences encode an intracellular protein. Therefore, polynucleotides are contemplated that have at least 80%, preferably at least 85%, more preferably at least 90% and most preferably at least 95% identity with the sequences of SEQ ID NO:1 - SEQ ID NO:7, so long as contemplated polynucleotides encode an intracellular protein.

For example, point mutations may arise at any position of the sequence from an apurinic, apyrimidinic, or otherwise structurally impaired site within the cDNA. Alternatively, point mutations may be introduced by random or site-directed mutagenesis procedures (*e.g.*, oligonucleotide assisted or by error prone PCR). Likewise, deletions and/or insertions may be introduced into the sequences, and particularly preferred insertions comprise 5'- and/or 3'-fusions with a polynucleotide that encodes a reporter moiety or an affinity moiety. Other particularly

preferred insertions comprise a nucleic acid that further includes functional elements such as a promoter, enhancer, hormone responsive element, origin of replication, transcription and translation initiation sites, etc. It should especially be appreciated that where insertions with one or more functional elements are present, the resulting nucleic acid may be linear or circular (e.g., transcription or expression cassettes, plasmids, etc.).

Still further contemplated variations include substitution of one or more atoms or chemical groups in the sequence with a radioactive atom or group. For example, where contemplated cDNAs are employed as a hybridization-specific probes, a fluorophor or enzyme (e.g.,  $\beta$ -galactosidase for generation of a dye, or luciferase for generation of luminescence) may be coupled to the sequence to identify position and/or quantity of a complementary sequence. Alternatively, where contemplated cDNA molecules are utilized for affinity isolation procedures, the cDNA may be coupled to a molecule that is known to have a high-affinity (i.e.,  $K_d < 10^{-4} \text{ mol}^{-1}$ ) partner, such as biotin, or an oligo-histidyl tag. In another example, one or more phosphate groups may be exchanged for a radioactive phosphate group with a  $^{32}\text{P}$  or  $^{33}\text{P}$  isotope to assist in detection and quantification, where the radiolabeled cDNA is employed as a hybridization probe.

It is also contemplated that the polypeptides (encoded by SEQ ID NO:1 – SEQ ID NO:7) having the peptide sequence of SEQ ID NO:8 – SEQ ID NO:14 may be produced *in vivo* or *in vitro*, and may be chemically and/or enzymatically modified. Contemplated polypeptides can be isolated from prostate tissue or prostate cancer cells that may or may not be in a hormone dependent state. Alternatively, and especially where larger amounts (i.e.,  $>10\text{mg}$ ) are desirable, recombinant production (e.g., in a bacterial, yeast, insect cell, or mammalian cell system) may advantageously be employed to generate significant quantities of contemplated polypeptides.

It should further be appreciated that recombinant production not only offers a more economical strategy to produce contemplated polypeptides, but also allows specific modification in the amino acid sequence and composition to tailor particular biochemical, catalytic and physical properties. For example, where increased solubility of contemplated polypeptides is desirable, one or more hydrophobic amino acids may be replaced with hydrophilic amino acids. Alternatively, where reduced or increased catalytic activity is required, one or more amino acids may be replaced or eliminated. In still another example, fusion proteins with contemplated proteins are contemplated, in which an additional polypeptide is added to the N-terminus and/or C-terminus

of contemplated polypeptide. Particularly contemplated fusion proteins include fusions with enzymatically active fusion partners (*e.g.*, for dye formation or substrate conversion) and fluorescent fusion partners such as GFP, EGFP, BFP, etc. Therefore, sequences other than the sequences of SEQ ID NO:8 – SEQ ID NO:14 are also contemplated, so long as the polypeptides are intracellular proteins, and alternative peptide sequences may have a sequence that has a 70%, preferably 80%, more preferably 90%, and most preferably 95% homology to the sequences of SEQ ID NO:8 – SEQ ID NO:14.

With respect to chemical and enzymatic modifications of contemplated polypeptides, it is contemplated that many modifications are appropriate, including addition of mono-, and bifunctional linkers, coupling with protein- and non-protein macromolecules, and glycosylation. For example, mono- and bifunctional linkers are especially advantageous where contemplated polypeptides are immobilized to a solid support, or covalently coupled to a molecule that enhances immunogenicity of contemplated polypeptides (*e.g.*, KLH, or BSA conjugation). Alternatively, contemplated polypeptides may be coupled to antibodies or antibody fragments to allow rapid retrieval of the polypeptide from a mixture of molecules. Further contemplated couplings include covalent and non-covalent coupling of contemplated polypeptides with molecules that prolong the serum half-life and/or reduce immunogenicity such as cyclodextranes and polyethylene glycols.

In a particularly contemplated aspect of the inventive subject matter, SEQ ID NO: 15 – SEQ ID NO:21 (the corresponding mRNA of SEQ ID NO: 1 – SEQ ID NO:7) are employed in a method of detecting a neoplastic cell in a system. In one step, a predetermined quantity of an RNA comprising at least one of SEQ ID NO:15 - SEQ ID NO:21 in a cell containing system is correlated with the presence of a neoplastic cell, wherein the RNA encodes an intracellular polypeptide, and in a further step, an amount of at least the predetermined quantity of the RNA is detected in the system.

In a preferred embodiment, the system is a mammal (most preferably a human) and the neoplastic cell is a prostate cancer cell in a biopsy specimen. The total RNA is extracted from the biopsy specimen, and a real time quantitative rt-PCR employing individual reactions with primer pairs specific to each of the sequences of SEQ ID NO:15 - SEQ ID NO:21 is performed in parallel with a biopsy specimen known to be free of cancer cells. Biopsy specimens are determined to have a cancer cell, where the detected mRNA quantity of SEQ ID NO:15 - SEQ ID

NO:21 is at least 3 times higher than in the control specimen. A preferred extraction of total RNA utilizes the Quiagen BioRobot kit in conjunction with the BioRobot 9600 system, and the real time rtPCR is performed in a Perkin Elmer ABI Prism 7700.

In alternative aspects of the inventive subject matter, the method of detecting a neoplastic cell need not be limited to biopsy tissues from prostate tissue, but may employ various alternative tissues, including lymphoma tumor cells, and various solid tumor cells, so long as such tumor cells overproduce mRNA of the SEQ ID NO:15 - SEQ ID NO:21. Appropriate alternative tumor cells can readily be identified by the above described method. Likewise, the system need not be restricted to a mammal, but may also include cell-, and tissue cultures grown *in vitro*, and tumor cells and specimens from animals other than mammals.

For example, tumor cell and tissue grown *in vitro* may advantageously be utilized to investigate drug action on such cells, and the overabundance of sequences of SEQ ID NO:15 - SEQ ID NO:21 may conveniently be employed as tumor marker. Alternatively, body fluids (*e.g.*, serum, saliva, etc.) that may or may not contain tumor cells are also contemplated a suitable substrate for the method presented herein, so long as they contain to at least some extent mRNA with a sequence of SEQ ID NO:15 - SEQ ID NO:21.

With respect to the detection method it is contemplated that many methods other than quantitative real time rt-PCR are also appropriate, and particularly contemplated methods include hybridization of a probe to at least one of SEQ ID NO:15 - SEQ ID NO:21. It is especially contemplated that suitable probes are labeled, and depending on the physico-chemical nature of the probe, the detection process may include fluorescence detection, luminescence detection, scintigraphy, autoradiography, and formation of a dye. For example, for microscopic analysis of biopsy specimens, fluorescein modified sequence probes (complementary to at least one of SEQ ID NO:15 - SEQ ID NO:21) are particularly advantageous. Fluorescence quantification may then be performed utilizing a CCD-video analysis package. Similarly, luminescence may be detected with a luminometer coupled to a microscope, or where tissue pieces are submerged in a sample cuvette, luminescence may be determined in the sample fluid. It should be appreciated that labeling of oligonucleotides and hybridization of the labeled oligonucleotide is a technique that is well known in the art, and that all known methods are generally suitable for use in conjunction with methods contemplated herein. Alternatively, the amount of mRNA may also be determined by first hybridizing a probe to the mRNA and subsequently enzymatically coupling of at least

one nucleotide to the probe, and especially contemplated enzymatic additions include LCR and PCR.

In still other aspects of contemplated methods, the mRNA quantity need not necessarily be limited to at least 3 times more than in the control specimen in order to establish that the tissue has a cancer cell. For example, where the concentration of mRNA is hormone dependent, higher amounts between 3-8 fold and more may be appropriate. In contrast, where the concentration of cancer cells in the biopsy specimen is relatively low, amounts of less than 3-fold, including 1.5 to 2.9-fold and less are contemplated.

In another particularly contemplated aspect of the inventive subject matter, polypeptide of SEQ ID NO: 8 - SEQ ID NO:14 (encoded by SEQ ID NO: 1 - SEQ ID NO:7) are employed in a method of detecting a neoplastic cell in a system. In one step, a predetermined quantity of an intracellular polypeptide comprising at least one of SEQ ID NO:8 - SEQ ID NO:14 in a cell containing system is correlated with the presence of a neoplastic cell, and in a further step, an amount of at least the predetermined quantity of the RNA is then detected in the system.

In a preferred embodiment, the system is a mammal (most preferably a human) and the neoplastic cell is a prostate cancer cell or a breast cancer cell in a biopsy specimen. The biopsy specimen that is suspected to have a cancer cell is flash frozen, dissected on a microtome, and sections are mounted on microscope slides. The sections are subsequently incubated with a fluorescein labeled antibody that is directed against an epitope of at least one of the polypeptides of SEQ ID NO:8 - SEQ ID NO:14. Fluorescence is detected with a fluorescence microscope coupled to a CCD-video camera and image analysis equipment. Biopsy specimens are determined to have a cancer cell, where the fluorescence signal/quantity of one or more cells is at least 3 times higher than in the control specimen.

In alternative aspects of the inventive subject matter, the method of detecting a neoplastic cell need not be limited to biopsy tissues from prostate tissue, but may employ various alternative tissues, including lymphoma tumor cells, and various solid tumor cells, so long as such tumor cells overproduce polypeptides of the SEQ ID NO:8 - SEQ ID NO:14. Appropriate alternative tumor cells can readily be identified by the above described method. Likewise, the system need not be restricted to a mammal, but may also include cell, and tissue cultures grown *in vitro*, and tumor cells and specimens from animals other than mammals. For example, tumor cell and

tissue grown *in vitro* may advantageously be utilized to investigate drug action on such cells, and the polypeptides of SEQ ID NO:8 - SEQ ID NO:14 may conveniently be employed as a tumor marker. Alternatively, body fluids (*e.g.*, serum, saliva, etc.) that may or may not contain tumor cells are also contemplated as suitable substrates for the method presented herein, so long as they contain to at least some extent the polypeptides of SEQ ID NO:8 - SEQ ID NO:14.

With respect to detection methods, it is contemplated that many methods other than fluorescence microscopy are also appropriate, and particularly contemplated methods include specific binding of a probe to at least one of SEQ ID NO:8 - SEQ ID NO:14. It is especially contemplated that suitable probes are labeled, and depending on the physico-chemical nature of the probe, the detection process may include fluorescence detection, luminescence detection, scintigraphy, autoradiography, and formation of a dye.

For example, for microscopic analysis of biopsy specimens, luciferase labeled probes are particularly advantageous in conjunction with a luminescence substrate (*e.g.*, luciferin). Luminescence quantification may then be performed utilizing a CCD-camera and image analysis system. Similarly, radioactivity may be detected via autoradiographic or scintigraphic procedures on a tissue section, in a fluid or on a solid support. Where the probe is a natural or synthetic ligand of contemplated polypeptides, particularly contemplated ligands include molecules with a chemical modification that increase the affinity to the polypeptide and/or induce irreversible binding to the polypeptide. For example, transition state analogs or suicide inhibitors for a particular reaction catalyzed by the polypeptide are especially contemplated. Labeling of antibodies, antibody fragments, small molecules, and binding of the labeled entity is a technique that is well known in the art, and it is contemplated that all known methods are generally suitable for use in conjunction with methods contemplated herein. Furthermore, the probe need not be limited to a fluorescein labeled antibody, and alternative probes include antibody fragments (*e.g.*, Fab, Fab', scFab, etc.).

In still other aspects of contemplated methods, the polypeptide quantity need not necessarily be limited to at least 3 times more than the control specimen in order to establish that the tissue has a cancer cell (*e.g.*, where the control reads 100ng, three times more than the control means 300ng). For example, where the concentration of the polypeptide is hormone dependent, higher amounts between 3-8 fold and more may be appropriate. In contrast, where the concen-

tration of cancer cells in the biopsy specimen is relatively low, amounts of less than 3-fold, including 1.5 to 2.9-fold and less are contemplated.

It should further be appreciated that the polynucleotides of SEQ ID NO:1- SEQ ID NO:7 and SEQ ID NO:15 - SEQ ID NO:21 may be employed as a therapeutic modality in an antisense DNA/RNA based therapy. Anti-sense therapy, for example, could be employed to inhibit, up-, or down-regulate transcription or translation of the genes corresponding to SEQ ID NO:1- SEQ ID NO:7. It should further be appreciated that an anti-sense approach may also include regulatory sequences associated with SEQ ID NO:1- SEQ ID NO:7 such as transcription enhancers, hormone responsive elements, ribosomal- and RNA polymerase binding sites, etc., which may be located upstream or downstream of SEQ ID NO:1- SEQ ID NO:7, and may have a distance of several ten base pairs to several ten thousand base pairs.

Alternatively, the polypeptides of SEQ ID NO:8- SEQ ID NO:14 may also be employed in an antibody based therapy or a small molecule drug therapy directed towards the polypeptides of SEQ ID NO:8- SEQ ID NO:14. For example, antibody based therapy could be employed to neutralize, or remove corresponding polypeptides of SEQ ID NO:8- SEQ ID NO:14 *in-vivo*, or to interfere with one or more cellular functions of contemplated polypeptides.

**Figures 1A and 1B** show a schematic and an amino acid based alignment between the cDNAs of SEQ ID NO:1 - SEQ ID NO:7, in which SEQ ID NO:1 is the full-length cDNA and SEQ ID NO:2 - SEQ ID NO:7 are splicing variants of SEQ ID NO:1. In the amino acid based alignment SEQ ID NO:8 is the corresponding polypeptide to SEQ ID NO:1, and SEQ ID NO:9 - SEQ ID NO:14 are the corresponding polypeptides to SEQ ID NO:2 - SEQ ID NO:6.

### **Examples**

The following examples illustrate the isolation and cloning of the sequences of SEQ ID NO:1 - SEQ ID NO:7 from normal prostate tissue and from prostate cancer cells. SEQ ID NO:8 - SEQ ID NO:14, and SEQ ID NO:15 - SEQ ID NO:21 are computer generated transcriptions and translations of SEQ ID NO:1 - SEQ ID NO:7, respectively.

The following examples also illustrate a general method of identifying differentially expressed genes in a target tissue, in which in one step a target tissue-specific cDNA library is provided that has a plurality of tissue-specific genes obtained by suppression subtractive



hybridization. In a subsequent step, a predetermined quantity of tissue-specific genes is immobilized on a solid phase to form a tissue-specific cDNA array, and a first nucleic acid preparation is hybridized to a first tissue-specific cDNA array to create a first hybridization pattern, wherein the first preparation is prepared from the target tissue without previously exposing the target tissue to a compound. In a further step, a second nucleic acid preparation is hybridized to a second tissue-specific cDNA array to create a second hybridization pattern, wherein the second preparation is prepared from the target tissue after previously exposing the target tissue to a compound. In yet a further step, the first and the second hybridization pattern are then compared to identify differentially expressed genes. This general method is especially contemplated where the compound comprises a hormone, or various other suitable ligands.

### Suppression Subtraction of Prostate Specific Genes

cDNA derived from poly(A)+ RNA of 10 different normal human tissues were subtracted against normal human prostate cDNA using suppression subtraction hybridization (SSH) (Diatchenko, L., Lau, Y.-F. C., Campbell, A.P., Chenchik, A., Moqadam, F., Huang, B., Lukyanov, S., Lukyanov, K., Gurskaya, N., Sverdlov, E.D., Siebert, P.D. (1996). *Proc. Natl. Acad. Sci. USA* 93, 6025-6030), and the resulting cDNA fragments were cloned into an appropriate vector. SSH was performed as described (Clontech PCR-Select Cloning Kit) using prostate poly(A)+ RNA against a pool of poly(A)+ RNA obtained from ten normal human tissues (heart, brain, placenta, lung, liver, skeletal muscle, kidney, spleen, thymus, and ovary). Upon secondary PCR amplification (12 cycles), reactions were extracted with phenol/chloroform and DNA was precipitated with EtOH.

The pellet was washed once with 70% EtOH. After drying, the DNA pellet was dissolved in 0.2xTE or dH<sub>2</sub>O and cut with RsaI in a 20 ul reaction for 2 hrs at 37C to excise adaptors. After digestion, reactions were run on a 1.5 % agarose gel, with molecular size markers on one side, at 5 V/cm, 40 min. The adaptor bands are excised and discarded, and cDNA bands were cut out and purified (QAIEX gel DNA purification kit) after running the gel backwards to concentrate the cDNA.

The purified DNA was subcloned into EcoRV-cut, dephosphorylated pZERO vector from Invitrogen. DH10B electrocompetent cells ( $>10^{10}$  efficiency) were transformed with a 1/5 dilution of 1µl of the ligation mix.

Colonies were picked and the presence of cDNA inserts confirmed by PCR with T7 and SP6 primers directly from the colonies. 10% of reactions were run on a 1.5% agarose gel to visualize amplified products. The colonies with inserts were grown and glycerol stocks (15%) were prepared and stored at -80C.

### Reverse Northern Blot and Sequence Analyses

Clones from the SSH library were amplified by PCR and spotted on nylon filters in 96-well format to generate two identical blots for each set of 92 clones (the remaining four spots were used for positive and negative controls). For probe preparation, the androgen-responsive prostate cancer cell line LNCaP (Horoszewicz, J.S., Leong, S.S., Kawinski, E., Karr, J.P., Rosenthal, H., Chu, T.M., Mirand, E.A., and Murphy, G.P. (1983). *Cancer Res.* 43, 1809-1818) was employed that was either untreated [the (-) probe] or treated with the synthetic androgen R1881 for 24 hours [the (+) probe]. Poly(A)+ RNA was isolated from these cells and was used to make the <sup>32</sup>P-labeled probes. After hybridization with the (-) and (+) probes, clones showing differential hybridization were selected for further analysis (*i.e.*, confirmation by a secondary reverse northern blot, and northern blotting).

Reverse northern screening on the cDNA clones were done essentially as described elsewhere (Hedrick, S.M., Cohen, D.I., Neilson, E.A., Davis, M.M. (1984) *Nature* 308, 149-153; Sakaguchi N, Berger CN, Melchers F (1986). *EMBO J* 5: 2139-2147). DNA (approximately 400 ng) from PCR amplification in step 6 was diluted in 200 µl of 0.4M NaOH, 10 mM EDTA and mixed well by pipetting. After incubation at 95°C for 5-10 min, the tubes were chilled on ice. Denatured DNA was blotted on two separate pieces of Zeta Probe GT+ membrane (Bio-Rad) using a dot-blot apparatus (Bio-Rad). Positive [Prostate specific antigen (PSA) cDNA] and negative [glyceraldehyde 3-phosphate dehydrogenase (G3PDH) cDNA] controls are included on each blot in duplicate. Membranes were rinsed with 2XSSC, air dried, and then baked at 80°C for 30 min. A typical example of a reverse northern analysis is shown in **Figure 2**. In each blot pair, PSA and G3PDH are included as positive and negative controls, respectively. It should be noted that there was substantial increase in PSA hybridization in the (+) blot (probe prepared from cells that have been stimulated by androgens) compared with the (-) blot (probe prepared from untreated cells), whereas there was no significant change in hybridization of G3PDH between the two blots. Arrowheads indicate differentially expressed clones.

As a control to verify the prostate specific nature of isolated sequences, positive clones were tested in a standard northern blot against RNA preparations of multiple non-prostate tissues and a typical blot is shown in **Figure 3**. Lanes 1-10, and 12-16 are RNA preparations from non-prostate tissues, lane 11 is a RNA preparation from prostate, lane 12 is a RNA preparation from testis.

*Probes:* The probes were random-prime radiolabeled using standard laboratory procedures. Unincorporated nucleotides were removed using prespun G25 columns (Bio-Rad), and specific activity was typically over  $5 \times 10^8$  cpm/ $\mu$ g.

*Hybridization:* 25 ml Hybridization mix (7% SDS, 0.5 M NaHPO<sub>4</sub>, 1mM EDTA) at 65°C is prewarmed, and 12.5 ml were used for prehybridization of each membrane for 5-10 min at 65°C. Probes were heat denatured at 95°C for 3-5 min and transferred to the prehybridization mix at 65°C. Hybridization was done at 65°C overnight.

*Washing:* Wash solution I (2xSSC and 1% SDS) and wash solution II (0.1xSSC and 0.5% SDS) were prewarmed. Membranes were washed once with Solution I and then Solution II for 30 min at 65°C, covered with plastic wrap and exposed to phosphorimager screen.

*Selection:* Clones showing differential expression between the (-) and (+) blots were picked. A secondary round of reverse northern analysis is performed for confirmation by spotting each clone in duplicate on each blot. To confirm hormone dependence, a time course of R1881 induction of LNCaP cells as well as the CWR22 xenograft model upon androgen ablation (Wainstein, M. A., He, F., Robinson, D., Kung, H. J., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., Kursh, E. D., and Pretlow, T.G. (1994). *Cancer Res.* 54, 6049-6052) and the androgen-independent CWR22R relapsed xenograft (Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H. J., de Vere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B., and Pretlow, T. G. (1996). *Cancer Res.* 56, 3042-6) was used.

*Sequence analysis:* Sequence analysis was performed by the dideoxy chain termination methods using an ABI automated sequencer. It should be appreciated that many more androgen responsive, differentially expressed genes can be identified and isolated using the cloning strategy outlined above, including genes expressed during various growth and developmental phases

of a diseased prostate, and genes expressed as a result of a drug regimen. Moreover, it is contemplated that not only differentially expressed prostate cancer genes can be identified and isolated, but also genes involved in other diseased states of human prostate, including benign prostate hyperplasia, etc.

#### **Isolation of Splice Variants (SEQ ID NO: 2 - SEQ ID NO: 7)**

Poly(A)<sup>+</sup> RNA was isolated from LNCaP cells treated with R1881 (a synthetic androgen) and from androgen dependent prostate cancer xenograft CWR22 grown in nude mice in the presence of androgens. cDNA was prepared and subjected to PCR using SEQ ID NO:1 specific primers and a primer pair designed to amplify the previously published prostate. The respective 5'-primers were located around the translation start site, while the 3'-primer for all reactions was located around the stop codon. Reaction products were loaded onto an agarose gel and separated as shown in **Figure 4**. Lane 1 is a marker, lane 2 is positive control with SEQ ID NO:1 as template. Lanes 3-5 are PCR products from CWR22 cells with SEQ ID NO:1 specific primers, while lanes 6-8 are PCR products from CWR22 cells with prostate specific 5'-primer. Lanes 9-11 are PCR products from LNCaP cells with SEQ ID NO:1 specific primers, and lanes 12-14 are PCR products from LNCaP cells with prostate specific primers. Lane 15 is marker.

Only reactions with SEQ ID NO:1 specific primers yielded detectable PCR products, with a major band at 680bp (SEQ ID NO:1), and two additional bands at about 500bp (SEQ ID NO:2) and 750bp (SEQ ID NO:3). When primers for 5'-RACE analysis were employed, four additional PCR products were obtained, corresponding to SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively. All bands were sequenced to confirm their identity. SEQ ID NO:7 was obtained both as a 3'-RACE product as well as a distinct clone from the PSL library.

#### **Localization of Intracellular Proteins encoded by SEQ ID NO: 1 - SEQ ID NO: 3**

To gain insight into the subcellular location of the polypeptides SEQ ID NO:8 - SEQ ID NO:10 (encoded by SEQ ID NO:1 - SEQ ID NO:3), C-terminal fusion constructs with GFP were produced in COS7 cells. The cells were fixed, stained with DAPI and visualized by phase contrast or fluorescence microscopy and representative images are shown in **Figure 5**. Photographs in lane A depict a GFP fusion protein with SEQ ID NO:9, the photographs in lane B depict a GFP fusion protein with SEQ ID NO:10, the photographs in lane C depict a GFP fusion protein with SEQ ID NO:8, and the photographs in lane D depict a GFP protein as a control. The poly-

peptide of SEQ ID NO: 8 displayed strong granular fluorescence predominantly around the nucleus, while the polypeptide of SEQ ID NO:9 and SEQ ID NO:10 showed exclusively nuclear and predominantly nuclear localization, respectively. Due to the lack of an identifiable leader sequence that would indicate an export of the polypeptides of SEQ ID NO:11 - SEQ ID NO:14, it is contemplated that the sequences SEQ ID NO:11 - SEQ ID NO:14 are also intracellular proteins.

### **Regulation of Expression by multiple Hormones**

Untreated LNCaP cells and hormone treated LNCaP cells were employed to determine the hormone dependence of expression of SEQ ID NO:1. Treatment was as follows: Testosterone (T) at  $10^{-8}$ M, dihydrotestosterone (DHT) at  $10^{-8}$ M, estradiol (E2) at  $10^{-8}$ M, progesterone (P) at  $10^{-8}$ M, dexamethasone (Dex) at  $10^{-7}$ M, 1, 25-dihydroxy-vitamin D3 (VitD3) at  $10^{-8}$ M, and triiodothyronine (T3) at  $10^{-7}$ M. The total RNA of the treated cells was isolated and used in a northern blot analysis with radiolabeled SEQ ID NO:1 as probe. Figure 6 shows the results of an autoradiograph of a northern blot as described above. 18S-RNA is shown as control for RNA integrity and loading. The relative induction of SEQ ID NO:1 is indicated at the bottom of the lanes as determined by phosphorimager analysis. It is contemplated that SEQ ID NO:2 - SEQ ID NO:7 are splice variants of SEQ ID NO:1, and consequently it is contemplated that the expression of all of SEQ ID NO:1 - SEQ ID NO:6 is hormone dependent, and particularly contemplated hormones include androgens, progesterones, estrogens and glucocorticoids.

Thus, specific embodiments and applications of methods and applications of differentially expressed genes in prostate cancer cells have been disclosed. It should be apparent, however, to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. The inventive subject matter, therefore, is not to be restricted except in the spirit of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms "comprises" and "comprising" should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that the referenced elements, components, or steps may be present, or utilized, or combined with other elements, components, or steps that are not expressly referenced.

-17-

## SEQUENCE LISTING

## SEQ ID NO:1

atggaaaacg aattgttctg ctggggcgtc ctggtgcacg cgcagtgggt gctgtcagcc 60  
gcacactgtt tccagaactc ctacaccatc gggctggggc tgcacagtct tgaggccgac 120  
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcaccg agagtacaac 180  
agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240  
gacaccatcc ggagcatcag cattgcttcg cagtgcccta ccgcggggaa ctcttgcttc 300  
gtttctggct ggggtctgct ggcgaacggc agaatgccta ccgtgctgca gtgctgaac 360  
gtgtcgggtg tgtctgagga ggtctgcagt aagctctatg acccgctgta ccacccagc 420  
atgttctgcg ccggcgagg gcaagaccag aaggactcct gcaacgggtg ctctgggggg 480  
cccctgatct gcaacgggta cttgcagggc cttgtgtctt tcggaaaagc ccggtgtggc 540  
caagttggcg tgccaggtgt ctacaccaac ctctgcaaat tcaactgagt gatagagaaa 600  
accgtccagg ccagttaa 618

## SEQ ID NO:2

atggaaaacg aattgttctg ctggggcgtc ctggtgcacg cgcagtgggt gctgtcagcc 60  
gcacactgtt tccagaactc ctacaccatc gggctggggc tgcacagtct tgaggccgac 120  
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcaccg agagtacaac 180  
agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240  
gacaccatcc ggagcatcag cattgcttcg cagtgcccta ccgcggggaa ctcttgcttc 300  
gtttctggct ggggtctgct ggcgaacggg tgactctggg gggcccctga tctgcaacgg 360  
gtacttgtag ggccttgtgt ctttcggaaa agccccgtgt ggccaagttg gcgtgccagg 420  
tgtctacacc aacctctgca aattcactga gtggatagag aaaaccgtcc aggccagtta 480  
a 481

## SEQ ID NO:3

atggaaaacg aattgttctg ctggggcgtc ctggtgcacg cgcagtgggt gctgtcagcc 60  
gcacactgtt tccagaactc ctacaccatc gggctggggc tgcacagtct tgaggccgac 120  
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcaccg agagtacaac 180

-18-

agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240  
 gacaccatcc ggagcatcag cattgcttcg cagtgccta ccgcggggaa ctcttgcttc 300  
 gtttctggct ggggtctgct gggaacggg gagctcacgg gtgtgtgtct gccctcttca 360  
 aggaggctct ctgcccagtc gcgggggctg acccagagct ctgcgtccca ggcagaatgc 420  
 ctaccgtgct gcagtgcgtg aacgtgtcgg tgggtgtctga ggaggctctgc agtaagctct 480  
 atgaccgcgt gtaccacccc agcatgttct gcgcggcgagg agggcaagac cagaaggact 540  
 cctgcaacgg tgactctggg ggggccctga tctgcaacgg gtacttgacg ggccttggtg 600  
 ctttcggaaa agccccgtgt tggccaagtt ggcgtgccag gtgtctacac caacctctgc 660  
 aaattcactg agtggataga gaaaaccgtc caggccagtt aa 702

SEQ ID NO:4

ggaatgagcc tggatccggg gagcccagag ggaagggctg ggaggcggga atcttgcttc 60  
 ggaaggactc agagagtcct gacttgaaat ctacgccag tgctgagtct ctagtgaact 120  
 aagctcctac accatcgggc tgggcctgca cagtcttgag gccgaccaag agccaggag 180  
 ccagatgggtg gaggccagcc tctccgtacg gcaccagag tacaacagac ccttgctcgc 240  
 taacgacctc atgctcatca agttggacga atccgtgtcc gagtctgaca ccatccggag 300  
 catcagcatt gcttcgcagt gccctaccgc ggggaactct tgccctgctt ctggctgggg 360  
 tctgctggcg aacggtgaac tcacgggtgt gtgtctgccc tcttcaagga ggcctctgc 420  
 ccagtcgcgg gggctgaccc agagctctgc gtcccaggca gaatgcctac cgtgctgcag 480  
 tgcgtgaacg tgctgggtgt gtctgaggag gtctgcagta agctctatga cccgctgtac 540  
 cccccagca tggtctgcgc cggcggaggg caagaccaga aggactcctg caacggtgac 600  
 tctggggggc ccctgatctg caacgggtac ttgcagggcc ttgtgtcttt cggaaaagcc 660  
 ccgtgtggcc aagttggcgt gccaggtgtc tacaccaacc tctgcaaatt cactgagtgg 720  
 atagagaaaa ccgtccaggc cagttaactc tggggactgg gaacccatga aattgacccc 780  
 caaatacatc ctgcggaagg aattcaggaa tatctgatcc cagccctcc tccc 834

SEQ ID NO:5

ggaatgagcc tggatccggg gagcccagag ggaagggctg ggaggcggga atcttgcttc 60  
 ggaaggactc agagagtcct gacttgaaat ctacgccag tgctgagtct ctagtgaact 120

-19-

aagctcctac accatcgggc tgggcctgca cagtcttgag gccgaccaag agccagggag 180  
 ccagatgggtg gagggcagcc tctccgtacg gcacccagag tacaacagac ccttgctcgc 240  
 taacgacctc atgctcatca agttggacga atccgtgtcc gagtctgaca ccatccggag 300  
 catcagcatt gcttcgcagt gccctaccgc ggggaactct tgccctcgttt ctggctgggg 360  
 tctgctggcg aacggcagaa tgccctaccgt gctgcagtgc gtgaacgtgt cggtggtgtc 420  
 tgaggaggtc tgcagtaagc 440

## SEQ ID NO:6

ggctctggga ggaggacgga atgagcctgg atccggggag cccagagggga agggctggga 60  
 ggcgggaatc ttgcttcgga aggactcaga gagccctgac ttgaaatctc agcccagtgc 120  
 tgagtctcta gtgaactaag ctccctacacc atcgggctgg gcctgcacag tcttgaggcc 180  
 gaccaagagc cagggagcca gatggtggag gccagcctct ccgtacggca cccagagtac 240  
 aacagaccct tgctcgctaa cgacctcatg ctcatcaagt tggacgaatc cgtgtccgag 300  
 tctgacacca tccggagcat cagcattgct tgcagtgcc ctaccgcggg gaactcttgc 360  
 ctcgtttctg gctggggtct gctggcgaac ggcagaatgc ctaccgtgct gcagtgcgtg 420  
 aacgtgtcgg tgggtgtctga ggaggtctgc agtaagc 457

## SEQ ID NO:7

accaccccag catgttctgc gccggcggag agcaagacca gaaggactcc tgcaacgtga 60  
 gagaggggaa aggggagggc aggcgactca gggaaggggtg gagaaggggg agacagagac 120  
 acacagggcc gcatggcgag atgcagagat ggagagacac acagggagac agtgacaact 180  
 agagagagaa actgagagaa acagggaaat aaacacagga ataaagagaa gcaaagggaag 240  
 agagaaacag aaacagacat gggggaggca gaaacacaca cacatagaaa tgcagctgac 300  
 cttccaacag catggggcct gagggcggtg acctccaccc aacagaaaat cctcttataa 360  
 cttttgactc cccaaaaaac ctgactagaa atagcctact gttgacgggg gagccttacc 420  
 aataacataa atagtcgatt tatgcatacg ttttatgcat tcatgatata cttttgttgg 480  
 aattttttga tattttctaag ctacacagtt cgtctgtgaa tttttttaa ttgttgcaac 540  
 tctcctaaaa ttttttctaa tgtgtttatt gaaaaaaatc caagtataag tggacttgtg 600  
 cagttcaaac cagggttgtt caaggggtcaa ctgtgt 636



## SEQ ID NO:8

auggaaaacg aauguuucug cucggg'gcug cuggugcauc cgcagugggu gcugucagcc 60  
gcacacuguu uccagaacuc cuacaccauc gggcuggggcc ugcacagucu ugaggccgac 120  
caagagccag ggagccagau gguggaggcc agccucuccg uacggcacc cagaguacaac 180  
agacccuugc ucgcuaacga ccucaugcuc aucaaguugg acgaauccgu guccgagucu 240  
gacaccaucc ggagcaucag cauugcuucg cagugcccua ccgcggggaa cucuugccuc 300  
guuucuggcu ggggucugcu ggcgaacggc agaaugccua ccgugcugca gugcgugaac 360  
gugucggugg ugucugagga ggucugcagu aagcucuaug acccgugua ccacccagc 420  
auguucugcg cggcgaggagg gcaagaccag aaggacuccu gcaacgguga cucugggggg 480  
ccccugaucu gcaacgggua cuugcagggc cuugugucu ucggaaaagc cccguguggc 540  
caaguuggcg ugccaggugu cuacaccaac cucugcaau ucacugagug gauagagaaa 600  
accguccagg ccaguuaa 618

## SEQ ID NO:9

auggaaaacg aauguuucug cucggg'gcug cuggugcauc cgcagugggu gcugucagcc 60  
gcacacuguu uccagaacuc cuacaccauc gggcuggggcc ugcacagucu ugaggccgac 120  
caagagccag ggagccagau gguggaggcc agccucuccg uacggcacc cagaguacaac 180  
agacccuugc ucgcuaacga ccucaugcuc aucaaguugg acgaauccgu guccgagucu 240  
gacaccaucc ggagcaucag cauugcuucg cagugcccua ccgcggggaa cucuugccuc 300  
guuucuggcu ggggucugcu ggcgaacggg ugacucuggg gggccccuga ucugcaacgg 360  
guacuugcag ggccuugguc uuucggaaaa gccccgugug gccaaguugg cgugccaggu 420  
gucuacacca accucugcaa auucacugag uggauagaga aaaccgucca ggccaguuaa 480

## SEQ ID NO:10

auggaaaacg aauguuucug cucggg'gcug cuggugcauc cgcagugggu gcugucagcc 60  
gcacacuguu uccagaacuc cuacaccauc gggcuggggcc ugcacagucu ugaggccgac 120  
caagagccag ggagccagau gguggaggcc agccucuccg uacggcacc cagaguacaac 180  
agacccuugc ucgcuaacga ccucagcuca ucaaguugga cgaauccgug uccgagucug 240  
acaccauccg gagcaucagc auugcuucgc agugcccuac cgcggggaa ucuuugccucg 300

-21-

uuucuggcug gggucugcug gcgaacggug agcucacggg ugugugucug cccucuuaa 360  
 ggagguccuc ugcccagucg cgggggcuga cccagagcuc ugcguccag gcagaaugcc 420  
 uaccgugcug cagugcguga acgugucggg ggugucugag gaggucugca guaagcucua 480  
 ugacccgcug uaccacccca gcauguucug cgccggcgga gggcaagacc agaaggacuc 540  
 cugcaacggg gacucugggg gggcccugau cugcaacggg uacuugcagg gccuuguguc 600  
 uuucggaaaa gccccguguu ggccaaguug gcgugccagg ugucuacacc aaccucugca 660  
 aaauacuga guggauagag aaaaccgucc aggccaguu a 701

SEQ ID NO:11

ggaaugagcc uggauccggg gagcccagag ggaagggcug ggaggcggga aucuugcuuc 60  
 ggaaggacuc agagaguccg acuugaaauc ucagcccagu gcugagucuc uagugaacua 120  
 agcuccuaca ccaucgggcu gggccugcac agucuagagg ccgaccaaga gccagggagc 180  
 cagaggugga ggccagccuc uccguacggc acccagagua caacagaccc uugcucgcu 240  
 acgaccucau gcucaucaag uuggacgaau ccguguccga gucugacacc auccggagca 300  
 ucagcauugc uucgcagugc ccuaccgagg ggaacucuug ccucguuucu ggcugggguc 360  
 ugcugggcga cgggaacuca cgggugugug ucugcccucu ucaaggaggu ccucugccca 420  
 gucgcggggg cugacccaga gcucugcguc ccaggcagaa gccuaccgug cugcagugcg 480  
 ugaacguguc gguggugucu gaggaggucu gcaguaagcu cuaugacccg cuguaccacc 540  
 ccagcauguu cugcgccggc ggaggggcaag accagaagga cuccugcaac ggugacucug 600  
 gggggccccc gaucugcaac ggguacuugc agggccuugu gucuucgga aaagccccgu 660  
 guggccaagu uggcgugcca ggugucuaca ccaaccucug caaaauacu gaguggauag 720  
 agaaaaccgu ccaggccagu uaacucuggg gacugggaac ccaugaaau gacccccaaa 780  
 uacauccugc ggaaggaaau caggaaauuc ugaucccagc ccuccuccc 830

SEQ ID NO:12

ggaaugagcc uggauccggg gagcccagag ggaagggcgg gaggcgggaa ucuugcuucg 60  
 gaaggacuca gagagcccug acuugaaauc ucagcccagu gcugagucuc uagugaacua 120  
 agcuccuaca ccacgggcu gggcugcaca gucuugaggc cgaccaagag ccagggagcc 180  
 agauggugga ggccagccuc uccguacggc acccagagua caacagaccc uugcucgcu 240  
 acgaccucau gcucaucaag uuggacgaau ccguguccga gucugacacc auccggagca 300

-22-

ucagcauugc uucgcagugc ccuaccgcgg ggaacucuug ccucguuucu ggcugggguc 360  
 ugucggcgaa cggcagaaug ccuaccgugc ugcagugcgu gaacgugucg guggugucug 420  
 aggaggucug caguaagc 438

## SEQ ID NO:13

gcucugggag gaggacggaa ugagccugga uccggggagc ccagagggaa ggcugggag 60  
 gcgggaauucu ugcuucggaa ggacucagag agcccugacu ugaaaucuca gcccagugcu 120  
 gagucucuag ugaacuaagc uccuacacca ucgggcuggg ccugcacagu cuugaggccg 180  
 accaagagcc agggagccag augguggagg ccagccucuc cguacggcac ccagaguaca 240  
 acagaccuu gcucgcuaac gaccucaugc caucaaguug gacgaauccg uguccgaguc 300  
 ugacaccauc cggagcauca gcauugcuuc gcagugccu accgcgggga acucuugccu 360  
 cguuucuggc uggggucugc uggcgaacgg cagaauccu accgugcugc agugcgugaa 420  
 cgugucggug gugucugagg aggucugcag uaagc 455

## SEQ ID NO:14

accaccccag cauguucugc gccggcgag agcaagacca gaaggacucc ugcaacguga 60  
 gagaggggaa aggggagggc aggcgacuca ggggaaggug gagaagggg agacagagac 120  
 acacagggcc gcauggcgag augcagagau ggagagacac acagggagac agugacaacu 180  
 agagagagaa acugagagaa acagggaaau aaacacagga auaaagagaa gcaaaggaag 240  
 agagaaacag aaacagacau gggggaggca gaaacacaca cacauagaaa ugcagcugac 300  
 cuuccaacag cauggggccu gagggcgug accuccaccc aacagaaaau ccucuuaaua 360  
 cuuugacuc ccaaaaaaac cugacuagaa auagccuacu guugacgggg gagccuacc 420  
 aauaacauaa auagucgauu uaugcauacg uuuuaucau ucaugauuaa ccuuuguugg 480  
 aauuuuuga uauuucuaag cuacacaguu cgucugugaa uuuuuuuaa uuguugcaac 540  
 ucuccuaaaa uuuuuucuaa uguguuuau gaaaaaauc caaguaaagu ggacuugugc 600  
 aguucaaacc agguuguuuc aagggucaac ugugu 635

## SEQ ID NO:15

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp  
 Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu

-23-

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val  
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu  
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser  
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly  
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met  
Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu Val  
Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala  
Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly  
Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys  
Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu Cys  
Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser

SEQ ID NO:16

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp  
Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu  
Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val  
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu  
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser  
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly  
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly

SEQ ID NO:17

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp  
Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu  
Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val  
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu  
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser  
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly  
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Glu Leu  
Thr Gly Val Cys Leu Pro Ser Ser Arg Arg Ser Ser Ala Gln Ser Arg

Gly Leu Thr Gln Ser Ser Ala Ser Gln Ala Glu Cys Leu Pro Cys Cys  
Ser Ala

SEQ ID NO:18

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro  
Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser  
Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr  
Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly  
Glu Leu Thr Gly Val Cys Leu Pro Ser Ser Arg Arg Ser Ser Ala Gln  
Ser Arg Gly Leu Thr Gln Ser Ser Ala Ser Gln Ala Glu Cys Leu Pro  
Cys Cys Ser Ala

SEQ ID NO: 19

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro  
Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser  
Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr  
Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly  
Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu  
Glu Val Cys Ser Lys

SEQ ID NO:20

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro  
Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser  
Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr  
Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly  
Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu  
Glu Val Cys Ser Lys

SEQ ID NO:21

Ala Ile Ser Ser Gln Val Phe Trp Gly Val Lys Ser Tyr Lys Arg Ile  
Phe Cys Trp Val Glu Val Thr Ala Leu Arg Pro His Ala Val Gly Arg  
Ser Ala Ala Phe Leu Cys Val Cys Val Ser Ala Ser Pro Met Ser Val  
Ser Val Ser Leu Phe Leu Cys Phe Ser Leu Phe Leu Cys Leu Phe Pro  
Cys Phe Ser Gln Phe Leu Ser Leu Val Val Thr Val Ser Leu Cys Val  
Ser Pro Ser Leu His Leu Ala Met Arg Pro Cys Val Ser Leu Ser Pro  
Pro Ser Pro Pro Phe Pro Glu Ser Pro Ala Leu Pro Phe Pro Leu Ser  
His Val Ala Gly Val Leu Leu Val Leu Leu Ser Ala Gly Ala Glu His  
Ala Gly Val

[illegible]

## CLAIMS

What is claimed is:—

1. A polynucleotide comprising the nucleotide sequence of SEQ ID NO:3, wherein the nucleotide sequence encodes an intracellular protein.
2. The polynucleotide of claim 1 wherein the intracellular protein has a predominantly nuclear localization in a cell.
3. A polynucleotide comprising the nucleotide sequence of SEQ ID NO:4, wherein the nucleotide sequence encodes an intracellular protein.
4. A polynucleotide comprising the nucleotide sequence of SEQ ID NO:7, wherein the nucleotide sequence encodes an intracellular protein.
5. The polynucleotide of any one of claim 1, 3, or 4 wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.
6. The polynucleotide of any one of claims 1, 3, or 4 wherein the expression of the polynucleotide is dependent on at least one of an androgen, a progesterone, an estrogen, and a glucocorticoid.
7. A polynucleotide having at least 90% identity to at least one of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7, wherein the polynucleotide encodes an intracellular protein.
8. A polynucleotide having at least 95% identity to at least one of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7, wherein the polynucleotide encodes an intracellular protein.
9. A polypeptide comprising the amino acid sequence of SEQ ID NO:10, wherein the amino acid sequence is expressed *in vivo* in a prostate cancer cell.
10. The polypeptide of claim 9 wherein the polypeptide has a predominantly nuclear localization in a cell.

11. A polypeptide comprising the amino acid sequence of SEQ ID NO:11, wherein the amino acid sequence is expressed *in vivo* in a prostate cancer cell.
12. A polypeptide comprising the amino acid sequence of SEQ ID NO:14, wherein the amino acid sequence is expressed *in vivo* in a prostate cancer cell.
13. A polypeptide having at least 90% homology to at least one of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:14, wherein the polypeptide is an intracellular protein.
14. A polypeptide having at least 95% homology to at least one of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:14, wherein the polypeptide is an intracellular protein.
15. A method of detecting a neoplastic cell, comprising:  
correlating a predetermined quantity of an RNA comprising at least one of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:21 in a cell containing system with a presence of a neoplastic cell, wherein the RNA encodes an intracellular polypeptide; and  
detecting at least the predetermined quantity of the RNA in the system.
16. The method of claim 15 wherein the neoplastic cell is a prostate cancer cell.
17. The method of claim 15 wherein the system is a mammal.
18. The method of claim 15 wherein the step of detecting includes hybridization of a probe to at least one of the SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:21.
19. The method of claim 18 wherein the probe carries a label that is detected by a process selected from the group consisting of fluorescence detection, luminescence detection, scintigraphy, autoradiography, and formation of a dye.
20. The method of claim 18 wherein at least one nucleotide is enzymatically coupled to the probe while the probe is hybridized to the at least one of the SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:21.
21. A method of detecting a neoplastic cell, comprising:  
correlating a predetermined quantity of an intracellular polypeptide comprising at least one of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:14 in a cell containing system with a presence of a neoplastic cell; and



detecting at least the predetermined quantity of the intracellular polypeptide in the system.

22. The method of claim 21 wherein the neoplastic cell is a prostate cancer cell or a breast cancer cell.
23. The method of claim 21 wherein the system is a mammal.
24. The method of claim 21 wherein the step of detecting includes specifically binding of a probe to the polypeptide.
25. The method of claim 24 wherein the probe is selected from the group consisting of an antibody, an antibody fragment, a natural ligand of the polypeptide, and a synthetic ligand of the polypeptide.
26. The method of claim 24 wherein the probe carries a label that is detected by a process selected from the group consisting of fluorescence detection, luminescence detection, scintigraphy, autoradiography, and formation of a dye.
27. A method of identifying differentially expressed genes in a target tissue, comprising:  
providing a target tissue-specific cDNA library having a plurality of tissue-specific genes, wherein the tissue-specific genes are obtained by suppression subtractive hybridization;  
immobilizing a predetermined quantity of tissue-specific genes on a solid phase to form a tissue-specific cDNA array;  
hybridizing a first nucleic acid preparation to a first tissue-specific cDNA array to create a first hybridization pattern, wherein the first preparation is prepared from the target tissue without previously exposing the target tissue to a compound;  
hybridizing a second nucleic acid preparation to a second tissue-specific cDNA array to create a second hybridization pattern, wherein the second preparation is prepared from the target tissue after previously exposing the target tissue to a compound; and  
comparing the first and the second hybridization pattern to identify differentially expressed genes.

- | Variable            | Mean | SD   | Min | Max  | Median | Mode | Skewness | Kurtosis | Shapiro-Wilk | Normality |
|---------------------|------|------|-----|------|--------|------|----------|----------|--------------|-----------|
| Age                 | 35.5 | 10.5 | 20  | 65   | 35     | 35   | 0.1      | 3.0      | 0.95         | Normal    |
| Gender              | 1.5  | 0.5  | 1   | 2    | 1      | 1    | 0.0      | 0.0      | 0.99         | Normal    |
| Marital Status      | 1.5  | 0.5  | 1   | 2    | 1      | 1    | 0.0      | 0.0      | 0.99         | Normal    |
| Education           | 12.5 | 2.5  | 9   | 16   | 12     | 12   | 0.1      | 3.0      | 0.95         | Normal    |
| Income              | 1500 | 500  | 500 | 3000 | 1200   | 1000 | 0.2      | 3.5      | 0.90         | Normal    |
| Occupation          | 1.5  | 0.5  | 1   | 2    | 1      | 1    | 0.0      | 0.0      | 0.99         | Normal    |
| Health Status       | 1.5  | 0.5  | 1   | 2    | 1      | 1    | 0.0      | 0.0      | 0.99         | Normal    |
| Stress Level        | 2.5  | 1.0  | 1   | 4    | 2      | 2    | 0.1      | 3.0      | 0.95         | Normal    |
| Life Satisfaction   | 3.5  | 1.0  | 1   | 5    | 3      | 3    | 0.1      | 3.0      | 0.95         | Normal    |
| Resilience          | 2.5  | 1.0  | 1   | 4    | 2      | 2    | 0.1      | 3.0      | 0.95         | Normal    |
| Emotional Stability | 3.5  | 1.0  | 1   | 5    | 3      | 3    | 0.1      | 3.0      | 0.95         | Normal    |
| Physical Health     | 3.5  | 1.0  | 1   | 5    | 3      | 3    | 0.1      | 3.0      | 0.95         | Normal    |
| Mental Health       | 3.5  | 1.0  | 1   | 5    | 3      | 3    | 0.1      | 3.0      | 0.95         | Normal    |
| Social Support      | 3.5  | 1.0  | 1   | 5    | 3      | 3    | 0.1      | 3.0      | 0.95         | Normal    |
| Life Satisfaction   | 3.5  | 1.0  | 1   | 5    | 3      | 3    | 0.1      | 3.0      | 0.95         | Normal    |
| Resilience          | 2.5  | 1.0  | 1   | 4    | 2      | 2    | 0.1      | 3.0      | 0.95         | Normal    |
| Emotional Stability | 3.5  | 1.0  | 1   | 5    | 3      | 3    | 0.1      | 3.0      | 0.95         | Normal    |
| Physical Health     | 3.5  | 1.0  | 1   | 5    | 3      | 3    | 0.1      | 3.0      | 0.95         | Normal    |
| Mental Health       | 3.5  | 1.0  | 1   | 5    | 3      | 3    | 0.1      | 3.0      | 0.95         | Normal    |
| Social Support      | 3.5  | 1.0  | 1   | 5    | 3      | 3    | 0.1      | 3.0      | 0.95         | Normal    |




Figure 1A

SEQ ID NO:8 : MENELFCGVLVHPQWVLSAAHCFQNSYITIGLGLHSLEADQEPGSCMVVEASLSVRHPEYNRPPLANDLMLIKLDESVSSESDTIRISISIASQCPTAGNSCLVSGWGLLANC : 110  
 SEQ ID NO:9 : MENELFCGVLVHPQWVLSAAHCFQNSYITIGLGLHSLEADQEPGSCMVVEASLSVRHPEYNRPPLANDLMLIKLDESVSSESDTIRISISIASQCPTAGNSCLVSGWGLLANC : 110  
 SEQ ID NO:10: MENELFCGVLVHPQWVLSAAHCFQNSYITIGLGLHSLEADQEPGSCMVVEASLSVRHPEYNRPPLANDLMLIKLDESVSSESDTIRISISIASQCPTAGNSCLVSGWGLLANC : 110  
 SEQ ID NO:11: -----MVVEASLSVRHPEYNRPPLANDLMLIKLDESVSSESDTIRISISIASQCPTAGNSCLVSGWGLLANC : 64  
 SEQ ID NO:12: -----MVVEASLSVRHPEYNRPPLANDLMLIKLDESVSSESDTIRISISIASQCPTAGNSCLVSGWGLLANC : 64  
 SEQ ID NO:13: -----MVVEASLSVRHPEYNRPPLANDLMLIKLDESVSSESDTIRISISIASQCPTAGNSCLVSGWGLLANC : 64

SEQ ID NO:8 : RMP-----TVLQCVNVSVVEEVSKLYDPLYHPSMFCAGGQDQKDSKNGDSGGPLICNGYLQGLVSPGKAPCGQVGVPGVYTNLCKFTENIEKTVOAS : 205  
 SEQ ID NO:9 : -----TVLQCVNVSVVEEVSKLYDPLYHPSMFCAGGQDQKDSKNGDSGGPLICNGYLQGLVSPGKAPCGQVGVPGVYTNLCKFTENIEKTVOAS : 205  
 SEQ ID NO:10: ELTGVCPLPSSRRSSAQSRGLTQSSAQAEPLPCCSA----- : 146  
 SEQ ID NO:11: ELTGVCPLPSSRRSSAQSRGLTQSSAQAEPLPCCSA----- : 100  
 SEQ ID NO:12: RMP-----TVLQCVNVSVVEEVSK----- : 85  
 SEQ ID NO:13: RMP-----TVLQCVNVSVVEEVSK----- : 85

Figure 1B

WO 00/71711

PCT/IB00/00673

2/4




Figure 2

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

3.2 kb →

Figure 3




Figure 4

FIG. 5




Figure 5




Figure 6

## SEQUENCE LISTING

&lt;110&gt; Saatcioglu, Fahri

&lt;120&gt; Differentially Expressed Genes in Prostate Cancer

&lt;130&gt; Sequences for 586.02-PCT

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 60/135,325

&lt;151&gt; 1999-05-20

&lt;150&gt; 60/135,333

&lt;151&gt; 1999-05-20

&lt;160&gt; 21

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 618

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

```
atggaaaacg aattgttctg ctcgggcgtc ctggtgcata cgcagtgggt gctgtcagcc 60
gcacactgtt tccagaactc ctacaccatc gggctggggc tgcacagtct tgaggccgac 120
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcacc agagtacaac 180
agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240
gacaccatcc ggagcatcag cattgcttcg cagtgccta ccgcggggaa ctcttgctc 300
gtttctggct ggggtctgct ggcgaacggc agaatgccta ccgtgctgca gtgctgaac 360
gtgtcgggtg tgtctgagga ggtctgcagt aagctctatg acccgctgta ccacccagc 420
atgttctgcg ccggcggagg gcaagaccag aaggactcct gcaacgggta ctctgggggg 480
cccctgatct gcaacgggta cttgcagggc cttgtgtctt tcgaaaagc cccgtgtggc 540
caagttggcg tgccagggtg ctacaccaac ctctgcaaat tctagtgtg gatagagaaa 600
accgtccagg ccagttaa                                     618
```

&lt;210&gt; 2

&lt;211&gt; 481

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```
atggaaaacg aattgttctg ctcgggcgtc ctggtgcata cgcagtgggt gctgtcagcc 60
gcacactgtt tccagaactc ctacaccatc gggctggggc tgcacagtct tgaggccgac 120
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcacc agagtacaac 180
```

```

agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240
gacaccatcc ggagcatcag cattgcttcg cagtgccta ccgcggggaa ctcttgctc 300
gtttctggct ggggtctgct ggcgaacggg tgactctggg gggccctga tctgcaacgg 360
gtacttgacg ggccttggtg ctttcggaaa agccccgtgt ggccaagttg gcgtgccagg 420
tgtctacacc aacctctgca aattcactga gtggatagag aaaaccgtcc aggccagtta 480
a 481

```

&lt;210&gt; 3

&lt;211&gt; 702

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

```

atggaaaacg aattgttctg ctccggcgctc ctggtgcatc cgcagtgggt gctgtcagcc 60
gcacactgtt tccagaactc ctacaccatc gggctgggac tgcacagtct tgaggccgac 120
caagagccag ggagccagat ggtggaggcc agcctctccg tacggcacc cagagtacaac 180
agacccttgc tcgctaacga cctcatgctc atcaagttgg acgaatccgt gtccgagtct 240
gacaccatcc ggagcatcag cattgcttcg cagtgccta ccgcggggaa ctcttgctc 300
gtttctggct ggggtctgct ggcgaacggg gagctcacgg gtgtgtgtct gccctcttca 360
aggaggtcct ctgccagtc gcgggggctg acccagagct ctgcgtccca ggcagaatgc 420
gtaccgtgct gcagtgcgtg aacgtgtcgg tgggtgtctga ggaggtctgc agtaagctct 480
atgacccgct gtaccacccc agcatgttct gcgcggcgcg agggcaagac cagaaggact 540
cctgcaacgg tgactctggg ggggccctga tctgcaacgg gtacttgacg ggccttggtg 600
ctttcggaaa agccccgtgt tggccaagtt ggcgtgccag gtgtctacac caacctctgc 660
aaattcactg agtggataga gaaaaccgtc caggccagtt aa 702

```

&lt;210&gt; 4

&lt;211&gt; 834

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

```

ggaatgagcc tggatccggg gagcccagag ggaagggtcg ggaggcggga atcttgcttc 60
ggaaggactc agagagtcct gacttgaaat ctcagcccag tgctgagtct ctagtgaact 120
aagctcctac accatcgggc tgggcctgca cagtcttgag gccgaccaag agccagggag 180
ccagatggtg gaggccagcc tctccgtacg gcacccagag tacaacagac ccttgctcgc 240
taacgacctc atgctcatca agttggacga atccgtgtcc gactctgaca ccatccggag 300
catcagcatt gcttcgcagt gccctaccgc ggggaactct tgcctcgttt ctggctgggg 360
tctgctggcg aacgggtgaac tcacgggtgt gtgtctgccc tcttcaagga ggtcctctgc 420
ccagtcgcgg gggctgaccc agagctctgc gtcccaggca gaatgcctac cgtgctgcag 480
tgctgtaacg tgtcggtggt gtctgaggag gtctgcagta agctctatga cccgctgtac 540
caccccagca tgttctgcgc cggcgagggg caagaccaga aggactcctg caacggtgac 600
tctggggggc ccctgatctg caacgggtac ttgcaggggc ttgtgtcttt cggaaaagcc 660
ccgtgtggcc aagttggcgt gccagggtgc tacaccaacc tctgcaaatt cactgagtgg 720
atagagaaaa ccgtccaggc cagttaactc tggggactgg gaacccatga aattgacccc 780
caaatacatc ctgcggaagg aattcaggaa tatctgatcc cagcccctcc tccc 834

```

&lt;210&gt; 5



&lt;211&gt; 440

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

```

ggaatgagcc tggatccggg gagcccagag ggaagggctg ggaggcggga atcttgcttc 60
ggaaggactc agagagccct gacttgaaat ctcagcccag tgctgagtct ctagtgaact 120
aagctcctac accatcgggc tgggcctgca cagtcttgag gccgaccaag agccagggag 180
ccagatggtg gaggccagcc tctccgtacg gcacccagag tacaacagac ccttgctcgc 240
taacgacctc atgctcatca agttggacga atccgtgtcc gagtctgaca ccatccggag 300
catcagcatt gcttcgcagt gccctaccgc ggggaactct tgccctgttt ctggctgggg 360
tctgctggcg aacggcagaa tgcctaccgt gctgcagtgc gtgaacgtgt cgggtggtgtc 420
tgaggaggtc tgcagtaagc

```

440

&lt;210&gt; 6

&lt;211&gt; 457

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

```

ggctctggga ggaggacgga atgagcctgg atccggggag cccagaggga agggctggga 60
ggcggaatc ttgcttcgga aggactcaga gagccctgac ttgaaatctc agcccagtg 120
tgagtctcta gtgaactaag ctctacacc atccgggtgg gcctgcacag tcttgaggcc 180
gaccaagagc cagggagcca gatggtggag gccagcctct cdgtacggca cccagagtac 240
aacagacctt tgctcgctaa cgacctcatg ctcacaaagt tggacgaatc cgtgtccgag 300
tctgacacca tccggagcat cagcattgct tgcagtgcc ctaccgctgg gaactcttgc 360
ctcgcttctg gctgggggtct gctggcgaac ggagaatgc ctaccgtgct gcagtgcgtg 420
aacgtgtcgg tgggtgtctga ggaggtctgc agtaagc

```

457

&lt;210&gt; 7

&lt;211&gt; 636

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

```

accaccccag catgttctgc gccggcggag agcaagacca gaaggactcc tgcaacgtga 60
gagaggggaa aggggagggc aggcgactca gggaaggggtg gagaaggggg agacagagac 120
acacagggcc gcatggcgag atgcagagat ggagagacac acagggagac agtgacaact 180
agagagagaa actgagagaa acagggaat aaacacagga ataaagagaa gcaaaggaag 240
agagaaacag aaacagacat gggggaggca gaaacacaca cacatagaaa tgcagctgac 300
cttccaacag catggggcct gagggcgggtg acctccaccc aacagaaaat cctcttataa 360
cttttgactc cccaaaaaac ctgactagaa atagcctact gttgacgggg gagccttacc 420
aataacataa atagtcgatt tatgcatacg ttttatgcat tcatgatata cctttgttgg 480
aatTTTTTga tatttctaa ctacacagtt cgtctgtgaa tttttttaa ttgttgcaac 540
tctcctaaaa ttttttctaa tgtgtttatt gaaaaaatc caagtataag tggacttgtg 600
cagttcaaac caggggtgtt caaggggtcaa ctgtgt

```

636

&lt;210&gt; 8

&lt;211&gt; 618

&lt;212&gt; RNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

```

auggaaaacg aauguuucug cucgggcguc cuggugcauc cgcagugggu gcugucagcc 60
gcacacuguu uccagaacuc cuacaccauc gggcuggggc ugcacagucu ugaggccgac 120
caagagccag ggagccagau gguggaggcc agccucuccg uacggcacc cagaguacaac 180
agaccuugc ucgcuaacga ccucaugcuc aucaaguugg acgaauccgu guccgagucu 240
gacaccaucc ggagcaucag cauugcuucg cagugcccua ccgcggggaa cucuugccuc 300
guuucuggcu ggggucugcu ggcgaacggc agaauGCCua ccgugcugca gugcgugaac 360
gugucggugg ugucugagga ggucugcagu aagcucuaug accgcugua cccccccagc 420
auguucugcg ccggcggagg gcaagaccag aaggacuccu gcaacgguga cucugggggg 480
ccccugaucu gcaacgggua cuugcagggc cuugugucuu ucggaaaagc cccguguggc 540
caaguuggcg ugccaggugu cuacaccaac cucugcaau ucacugagug gauagagaaa 600
accguccagg ccaguuaa 618

```

&lt;210&gt; 9

&lt;211&gt; 480

&lt;212&gt; RNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

```

auggaaaacg aauguuucug cucgggcguc cuggugcauc cgcagugggu gcugucagcc 60
gcacacuguu uccagaacuc cuacaccauc gggcuggggc ugcacagucu ugaggccgac 120
caagagccag ggagccagau gguggaggcc agccucuccg uacggcacc cagaguacaac 180
agaccuugc ucgcuaacga ccucaugcuc aucaaguugg acgaauccgu guccgagucu 240
gacaccaucc ggagcaucag cauugcuucg cagugcccua ccgcggggaa cucuugccuc 300
guuucuggcu ggggucugcu ggcgaacggg ugacucuggg gggccccuga ucugcaacgg 360
guacuugcag ggccuugguc uuucggaaaa gccccgugug gccaaguugg cgugccaggu 420
gucuaacca accucugcaa auucacugag uggauagaga aaaccgucca ggccaguuaa 480

```

&lt;210&gt; 10

&lt;211&gt; 701

&lt;212&gt; RNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

```

auggaaaacg aauguuucug cucgggcguc cuggugcauc cgcagugggu gcugucagcc 60
gcacacuguu uccagaacuc cuacaccauc gggcuggggc ugcacagucu ugaggccgac 120
caagagccag ggagccagau gguggaggcc agccucuccg uacggcacc cagaguacaac 180
agaccuugc ucgcuaacga ccucagcuca ucaaguugga cgaauccgug uccgagucug 240
acaccauccg gagcaucagc auugcuucgc agugcccua cgcgggggaac ucuugccucg 300
uuucuggcug ggggucugcug ggcgaacggg agcucacggg ugugugucug cccucuucaa 360
ggaggguccuc ugcccagucg cgggggcuga cccagagcuc ugcgucccag gcagaauGCC 420
uaccgugcug cagugcguga acgugcggg ggugucugag gaggucugca guaagcucua 480
ugacccgcug uaccaccca gcauguucug cgcggcgga gggcaagacc agaaggacuc 540
cugcaacggg gacucugggg gggcccugau cugcaacggg uacuugcagg gccuuguguc 600

```

uuucggaaaa gccccguguu ggccaaguug gcgugccagg ugucuacacc aaccucugca 660  
 aaauacuga guggauagag aaaaccgucc aggccaguua a 701

<210> 11  
 <211> 830  
 <212> RNA  
 <213> Homo sapiens

<400> 11  
 ggaaugagcc uggauccggg gagcccagag ggaagggcug ggaggcggga aucuugcuuc 60  
 ggaaggacuc agagaguccg acuugaaauc ucagcccagu gcugagucuc uagugaacua 120  
 agcuccuaca ccaucgggcu gggccugcac agucuugagg ccgaccaaga gccagggagc 180  
 cagaggugga ggccagccuc uccguacggc acccagagua caacagaccc uugcucgcu 240  
 acgaccucau gcucaucaag uuggacgaau ccguguccga gucugacacc auccggagca 300  
 ucagcauugc uucgcagugc ccuaccgcg ggaacucuug ccucguuucu ggcugggguc 360  
 ugcugggcga cgggaacuca cgggugugug ucugcccuc ucaaggaggu ccucugccca 420  
 gucgcggggg cugacccaga gcucugcguc ccaggcagaa gccuaccgug cugcagugcg 480  
 ugaacguguc gguggugucu gaggaggucu gcaguaagcu cuaugacccg cuguaccacc 540  
 ccagcauguu cugcgccggc ggagggaag accagaagga cuccugcaac ggugacucug 600  
 gggggccccc gaucugcaac ggguaucuug agggccuugu gucuucgga aaagccccgu 660  
 guggccaagu uggcgugcca ggugucuaca ccaaccucug caaauucacu gaguggauag 720  
 agaaaaccgu ccaggccagu uaacucuggg gacuggggaa ccaugaaau gacccccaaa 780  
 uacauccugc ggaaggaaau caggaauauc ugaucccagc ccuccuccc 830

<210> 12  
 <211> 438  
 <212> RNA  
 <213> Homo sapiens

<400> 12  
 ggaauagagcc uggauccggg gagcccagag ggaagggcgg gaggcgggaa ucuugcuucg 60  
 gaaggacuca gagagcccug acuugaaauc ucagcccagu gcugagucuc uagugaacua 120  
 agcuccuaca ccacgggcug ggcugcaca gucuugaggc cgaccaagag ccagggagcc 180  
 agauggugga ggccagccuc uccguacggc acccagagua caacagaccc uugcucgcu 240  
 acgaccucau gcucaucaag uuggacgaau ccguguccga gucugacacc auccggagca 300  
 ucagcauugc uucgcagugc ccuaccgcg ggaacucuug ccucguuucu ggcugggguc 360  
 ugcugggcga cggcagaaug ccuaccgugc ugcagugcgu gaacgugucg guggugucug 420  
 aggaggucug caguaagc 438

<210> 13  
 <211> 455  
 <212> RNA  
 <213> Homo sapiens

<400> 13  
 gcucugggag gaggacggaa ugagccugga uccggggagc ccagagggaa gggcugggag 60  
 gcgggaauuc ugcucggaa ggacucagag agcccugacu ugaaucuca gccagugcu 120  
 gagucucuag ugaacuaagc uccuacacca ucgggucggg ccugcacagu cuugaggccg 180

accaagagcc agggagccag augguggagg ccagccucuc cguacggcac ccagaguaca 240  
 acagaccuu gcucgcuaac gaccucaugc caucaaguug gacgaaucg uguccgaguc 300  
 ugacaccauc cggagcauca gcauugcuuc gcagugcccu accgcgggga acucuugccu 360  
 cguuucuggc ugaggucugc uggcgaacgg cagaauccu accgugcugc agugcgugaa 420  
 cgugucggug gugucugagg aggucugcag uaagc 455

<210> 14

<211> 635

<212> RNA

<213> Homo sapiens

<400> 14

accaccccag cauguucugc gccggcggag agcaagacca gaaggacucc ugcaacguga 60  
 gagaggggaa aggggagggc aggcgacuca ggaaggggug gagaaggggg agacagagac 120  
 acacagggcc gcauggcgag augcagagau ggagagacac acagggagac agugacaacu 180  
 agagagagaa acugagagaa acagggaaau aaacacagga auaaagagaa gcaaaggaag 240  
 agagaaacag aaacagacau gggggaggca gaaacacaca cacauagaaa ugcagcugac 300  
 cuuccaacag cauggggccu gagggcggug accuccaccc aacagaaaau ccucuuaaua 360  
 cuuuugacuc cccaaaaaac cugacuagaa auagccuacu guugacgggg gagccuuacc 420  
 auuaacauaa auagucgauu uaugcauacg uuuuaucau ucaugauaua ccuuuguugg 480  
 auuuuuuuga uauuucuaag cuacacaguu cgucugugaa uuuuuuuuuu uuguugcaac 540  
 ucuccuaaaa uuuuuucuaa uguguuuuuu gaaaaaaauc caaguaaagu ggacuugugc 600  
 aguucaaaacc agguuguuuc aggggucaac ugugu 635

<210> 15

<211> 205

<212> PRT

<213> Homo sapiens

<400> 15

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp

1 5 10 15

Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu.

20 25 30

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val

35 40 45

Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu

50 55 60

Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser

65 70 75 80

Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly

85 90 95

Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met  
 100 105 110

Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu Glu Val  
 115 120 125

Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala  
 130 135 140

Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly  
 145 150 155 160

Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys  
 165 170 175

Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn Leu Cys  
 180 185 190

Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser  
 195 200 205

<210> 16

<211> 110

<212> PRT

<213> Homo sapiens

<400> 16

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp  
 1 5 10 15

Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu  
 20 25 30

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val  
 35 40 45

Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu  
 50 55 60

Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser  
 65 70 75 80

Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly  
 85 90 95

Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly  
 100 105 110

<210> 17  
 <211> 146  
 <212> PRT  
 <213> Homo sapiens

<400> 17

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp  
 1 5 10 15

Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu  
 20 25 30

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val  
 35 40 45

Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu  
 50 55 60

Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser  
 65 70 75 80

Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly  
 85 90 95

Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Glu Leu  
 100 105 110

Thr Gly Val Cys Leu Pro Ser Ser Arg Arg Ser Ser Ala Gln Ser Arg  
 115 120 125

Gly Leu Thr Gln Ser Ser Ala Ser Gln Ala Glu Cys Leu Pro Cys Cys  
 130 135 140

Ser Ala  
 145

<210> 18  
 <211> 100  
 <212> PRT  
 <213> Homo sapiens

<400> 18

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro  
 1 5 10 15

Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser  
 20 25 30

Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr  
 35 40 45

Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly  
 50 55 60

Glu Leu Thr Gly Val Cys Leu Pro Ser Ser Arg Arg Ser Ser Ala Gln  
 65 70 75 80

Ser Arg Gly Leu Thr Gln Ser Ser Ala Ser Gln Ala Glu Cys Leu Pro  
 85 90 95

Cys Cys Ser Ala  
 100

<210> 19

<211> 85

<212> PRT

<213> Homo sapiens

<400> 19

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro  
 1 5 10 15

Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser  
 20 25 30

Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr  
 35 40 45

Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly  
 50 55 60

Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu  
 65 70 75 80

Glu Val Cys Ser Lys  
 85

<210> 20

<211> 85

<212> PRT

<213> Homo sapiens

&lt;400&gt; 20

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro  
 1 5 10 15

Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser  
 20 25 30

Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr  
 35 40 45

Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly  
 50 55 60

Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu  
 65 70 75 80

Glu Val Cys Ser Lys  
 85

&lt;210&gt; 21

&lt;211&gt; 131

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

Ala Ile Ser Ser Gln Val Phe Trp Gly Val Lys Ser Tyr Lys Arg Ile  
 1 5 10 15

Phe Cys Trp Val Glu Val Thr Ala Leu Arg Pro His Ala Val Gly Arg  
 20 25 30

Ser Ala Ala Phe Leu Cys Val Cys Val Ser Ala Ser Pro Met Ser Val  
 35 40 45

Ser Val Ser Leu Phe Leu Cys Phe Ser Leu Phe Leu Cys Leu Phe Pro  
 50 55 60

Cys Phe Ser Gln Phe Leu Ser Leu Val Val Thr Val Ser Leu Cys Val  
 65 70 75 80

Ser Pro Ser Leu His Leu Ala Met Arg Pro Cys Val Ser Leu Ser Pro  
 85 90 95

Pro Ser Pro Pro Phe Pro Glu Ser Pro Ala Leu Pro Phe Pro Leu Ser  
 100 105 110



His Val Ala Gly Val Leu Leu Val Leu Leu Ser Ala Gly Ala Glu His  
 115 120 125

Ala Gly Val  
 130

115 120 125 130

Practitioner's Docket No. 586.02-US1

PATENT

---

**COMBINED DECLARATION AND POWER OF ATTORNEY**  
**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,**  
**CONTINUATION, OR C-I-P)**

---

As a below named inventor, I hereby declare that:

**TYPE OF DECLARATION**

This declaration is for a national stage of PCT application.

**INVENTORSHIP IDENTIFICATION**

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

**TITLE OF INVENTION**

DIFFERENTIALLY EXPRESSED GENES IN PROSTATE CANCER

**SPECIFICATION IDENTIFICATION**

The specification was described and claimed in PCT International Application No. PCT/IB00/00673 filed on May 19, 2000.

**ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR**

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56, and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent.

**PRIORITY CLAIM (35 U.S.C. Section 119(a)-(d))**

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international

application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Such applications have been filed as follows.

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)**  
(35 U.S.C. Section 119(e))


I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER	FILING DATE
60/135,325	May 20, 1999
60/135,333	May 20, 1999

**POWER OF ATTORNEY**

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

APPOINTED PRACTITIONER(S)	REGISTRATION NUMBER(S)
Robert D. Fish	<u>33880</u>
David J. Zoetewey	<u>45258</u>
Sandra P. Thompson	<u>46264</u>
Martin Fessenmaier	<u>46697</u>
Bruce Fertel	<u>41742</u>



I hereby appoint the practitioner(s) associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

## SEND CORRESPONDENCE TO

Robert D. Fish  
1440 N. Harbor Blvd.  
Suite 706  
Fullerton, CA 92835  
USA

## DIRECT TELEPHONE CALLS TO:

Robert D. Fish  
(714) 449-2337

Customer Number 24392

## DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

## SIGNATURE(S)

1-00  
Fahri SAATCIOGLU  
Inventor's signature


Date 8 Jan 2001

Country of Citizenship Turkey

Residence Frognerseterveien 40 D, 0776 Oslo, Norway

Post Office Address University of Oslo  
Biotechnology Center of Oslo  
PO Box 1125  
Gaustadallen 21  
N-Oslo N-1317 Blindern  
NORWAY

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☒ Scanned copy is best available.

*Drawing.*